Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Survival of Non-Small Cell Lung Carcinoma EGFR Non-mutated (Wild Type) Patients Treated With Erlotinib (TARceva) After the Failure of at Least One Chemotherapy Regimen

NCT01990261 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01990261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01990261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Survival of Non-Small Cell Lung Carcinoma EGFR Non-mutated (Wild Type) Patients Treated With Erlotinib (TARceva) After the Failure of at Least One Chemotherapy Regimen
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Terminated
Start date
May 31, 2013
Completion date
September 30, 2014
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer